In situ delivery of therapeutic proteins by recombinant Lactococcus lactis

被引:0
|
作者
Steidler, L [1 ]
Neirynck, S [1 ]
机构
[1] Natl Univ Ireland Univ Coll Cork, Cork, Ireland
关键词
Lactococcus lactis; inflammatory bowel disease; thyA; interleukin-10;
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Chronic inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis, affects around 2 in every 1000 individuals in western countries and its incidence, particularly amongst children, is increasing. IBD shows extreme morbidity with impact on all aspects of quality of life. If left untreated, IBD can lead to death. Conventional treatment of IBD involves powerful immunosuppressive chemotherapies and surgical intervention. Long-term anti-inflammatory medication is required and so patients are often subject to a spectrum of unpleasant side effects. Interleukin-10 (IL-10) is a cytokine that acts to suppress inflammation. When however administered by injection, the high levels of IL-10 that are distributed throughout the body also lead to side effects. Lactococcus lactis can be genetically engineered to secrete biologically active cytokines. When applied to the mucosa, these L. lactis can actively deliver such cytokines. By use of this principle developed a new therapeutic approach for IBD. Administration of L. lactis that secretes murine IL-10 cures and prevents IBD in mice. The use of the engineered L lactis gets around the problem of delivering IL-10, allowing dramatic reduction of the effective dose. A sincere concern exists about the possible dangers of uncontrolled, deliberate release of genetically modified microorganisms, such as could occur following application in healthcare. We engaged in the establishment of adequate means for biological growth control of engineered L. lactis by targeted gene exchange between thyA and hIL-10.
引用
收藏
页码:63 / 72
页数:10
相关论文
共 50 条
  • [1] Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins
    Bahey-El-Din, Mohammed
    Gahan, Cormac G. M.
    Griffin, Brendan T.
    CURRENT GENE THERAPY, 2010, 10 (01) : 34 - 45
  • [2] Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins
    Bermudez-Humaran, Luis G.
    HUMAN VACCINES, 2009, 5 (04): : 264 - 267
  • [3] In situ delivery of cytokines by genetically engineered Lactococcus lactis
    Steidler, L
    ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY, 2002, 82 (1-4): : 323 - 331
  • [4] In situ delivery of cytokines by genetically engineered Lactococcus lactis
    Lothar Steidler
    Antonie van Leeuwenhoek, 2002, 82 : 323 - 331
  • [5] Therapeutic drug delivery by genetically modified Lactococcus lactis
    Steidler, Lothar
    Rottiers, Pieter
    INFLAMMATORY BOWEL DISEASE: GENETICS, BARRIER FUNCTION, IMMUNOLOGIC MECHANISMS, AND MICROBIAL PATHWAYS, 2006, 1072 : 176 - 186
  • [6] HtrA Is Essential for Efficient Secretion of Recombinant Proteins by Lactococcus lactis
    Sriraman, Kalpana
    Jayaraman, Guhan
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2008, 74 (23) : 7442 - 7446
  • [7] Progress in the development of Lactococcus lactis as a recombinant mucosal vaccine delivery system
    Norton, PM
    LePage, RWF
    Wells, JM
    FOLIA MICROBIOLOGICA, 1995, 40 (03) : 225 - 230
  • [8] Evolved Lactococcus lactis Strains for Enhanced Expression of Recombinant Membrane Proteins
    Linares, Daniel M.
    Geertsma, Eric R.
    Poolman, Bert
    JOURNAL OF MOLECULAR BIOLOGY, 2010, 401 (01) : 45 - 55
  • [9] In situ delivery of cytokines at mucosal surfaces by genetically engineered Lactococcus lactis
    Steidler, L
    NOVEL PROCESSES AND CONTROL TECHNOLOGIES IN THE FOOD INDUSTRY, 2001, 338 : 179 - 196
  • [10] Lactococcus lactis: From the Dairy Industry to Antigen and Therapeutic Protein Delivery
    Bahey-El-Din, Mohammed
    Gahan, Cormac G. M.
    DISCOVERY MEDICINE, 2010, 9 (48) : 455 - 461